Article
Hematology
Malvi Savani, Kwang W. Ahn, Yue Chen, Sairah Ahmed, Amanda F. Cashen, Mazyar Shadman, Dipenkumar Modi, Farhad Khimani, Corey S. Cutler, Jasmine Zain, Jonathan E. Brammer, Andrew R. Rezvani, Timothy S. Fenske, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Mehdi Hamadani
Summary: This study compared the outcomes of reduced-intensity/non-myeloablative conditioning (RIC/NMA) and myeloablative conditioning (MAC) regimens in T-cell non-Hodgkin lymphoma (T-NHL) patients undergoing allogeneic transplant (allo-HCT). The results showed no significant differences in overall survival, non-relapse mortality, risk of progression/relapse, and therapy failure between the two regimens.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Biophysics
Nobuhiko Imahashi, Seitaro Terakura, Eisei Kondo, Koji Kato, Sung-Won Kim, Akihito Shinohara, Mizuki Watanabe, Takahiro Fukuda, Naoyuki Uchida, Hikaru Kobayashi, Jun Ishikawa, Keisuke Kataoka, Souichi Shiratori, Takashi Ikeda, Ken-ichi Matsuoka, Shuro Yoshida, Tadakazu Kondo, Takafumi Kimura, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda
Summary: The study showed that UCB transplantation with optimal conditioning and GVHD prophylaxis had better outcomes compared to MRD and MUD transplantation, suggesting it is a highly effective treatment for mature lymphoid malignancies. This indicates that UCB transplantation might be preferred over MRD or MUD transplantation in certain settings.
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Dipenkumar Modi, Vijendra Singh, Seongho Kim, Lois Ayash, Abhinav Deol, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: When comparing outcomes of unrelated donor allogeneic peripheral blood stem cell transplantation for AML between reduced intensity conditioning and myeloablative conditioning regimens using thymoglobulin for GVHD prophylaxis, there was no significant difference in survival, relapse rates, or GVHD-free relapse-free survival between the two regimens. Thymoglobulin at 4.5 mg/kg did not have any adverse impact on survival when used with the reduced intensity conditioning regimen.
ANNALS OF HEMATOLOGY
(2021)
Article
Immunology
Agnieszka Tomaszewska, Madan Jagasia, Eric Beohou, Steffie van der Werf, Didier Blaise, Edward Kanfer, Noel Milpied, Peter Remenyi, Fabio Ciceri, Jean H. Bourhis, Patrice Chevallier, Carlos Solano, Gerard Socie, Benedetto Bruno, Alessandro Rambaldi, Luca Castagna, Nicolaus Kroger, Paolo Corradini, Boris Afanasyev, Marco Ladetto, Dietger Niederwieser, Christof Scheid, Henrik Sengeloev, Frank Kroschinsky, Ibrahim Yakoub-Agha, Helene Schoemans, Christian Koenecke, Olaf Penack, Zinaida Peric, Hildegard Greinix, Rafael F. Duarte, Grzegorz W. Basak
Summary: A retrospective analysis of 3839 adult patients with B-cell malignancies undergoing alloHCT found that adding rituximab to reduced intensity conditioning regimens did not significantly impact major transplant outcome variables. However, the lack of data on chronic GVHD in this study limits the conclusions that can be drawn.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Peter Dreger
Summary: With the development of modern targeted molecular therapies and immunotherapies, the traditional role of allogeneic hematopoietic cell transplantation in the treatment of non-Hodgkin lymphoma is being questioned.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Biophysics
Alexandros Spyridonidis, Myriam Labopin, Tobias Gedde-Dahl, Arnold Ganser, Matthias Stelljes, Charles Craddock, Eva Maria Wagner-Drouet, Jurjen Versluis, Thomas Schroeder, Igor Wolfgang Blau, Gerald. G. Wulf, Peter Dreger, Gitte Olesen, Henrik Sengeloev, Nicolaus Kroger, Victoria Potter, Edouard Forcade, Jakob Passweg, Regis Peffault de Latour, Johan Maertens, Keith M. O. Wilson, Jean Henri Bourhis, Juergen Finke, Eolia Brissot, Ali Bazarbachi, Sebastian Giebel, Bipin P. Savani, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: This study confirms the effectiveness of the recently developed transplant conditioning intensity (TCI) score in predicting mortality and relapse rates in hematopoietic cell transplantation.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Shlomo Elias, Samantha Brown, Sean M. Devlin, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A. Jakubowski, Oscar B. Lahoud, Heather Landau, Richard J. Lin, Esperanza B. Papadopoulos, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Brian C. Shaffer, Gunjan L. Shah, Roni Tamari, James W. Young, Miguel-Angel Perales, Roni Shouval
Summary: Comorbidity assessment is important before allogeneic haematopoietic cell transplantation (allo-HCT) to estimate non-relapse mortality (NRM) risk. The Simplified Comorbidity Index (SCI), which includes a small number of comorbidities and older age, has been shown to predict NRM. In this study, we validated the SCI in patients receiving reduced-intensity conditioning followed by allo-HCT from HLA-matched donors. Higher SCI scores were associated with increased NRM risk and reduced overall survival. These findings suggest that the SCI is a reliable tool for risk stratification in allo-HCT candidates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Oncology
Alessandro Broccoli, Pier Luigi Zinzani
Summary: The treatment of peripheral T-cell lymphomas is challenging and lacks effective strategies due to their severe prognosis. This article discusses three important questions: differentiating initial treatment based on histotype and clinical presentation, the necessity of autologous stem cell transplantation for all patients, and potential improvements in the setting of relapsed and refractory disease.
HEMATOLOGICAL ONCOLOGY
(2023)
Review
Oncology
Nicole C. Foley, Neha Mehta-Shah
Summary: This review focuses on the management of peripheral T-cell lymphoma, particularly the role of autologous and allogeneic stem cell transplant. The study finds that peripheral T-cell lymphomas are rare and have poorer outcomes compared to B-cell lymphomas. Transplant has been used to improve outcomes, but relapse remains a risk. The results of transplant are associated with disease control at the time of transplant, and treatment decisions are mostly based on clinical studies, retrospective series, and expert opinion.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Pharmacology & Pharmacy
Sharat Chandra, Kana Mizuno, Junfang Zhao, Stella M. Davies, Rebecca A. Marsh, Tsuyoshi Fukuda, Kenneth D. R. Setchell, Alexander A. Vinks, Parinda A. Mehta
Summary: The study demonstrates that using test-dose pharmacokinetics to predict full-dose pharmacokinetics of melphalan allows for accurate adjustment of melphalan dosage, preventing excess toxicity from increased systemic exposure, especially for patients with organ impairment.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Biophysics
Alberto Mussetti, Leyre Bento, Mariana Bastos-Oreiro, B. Rius Sansalvador, Carmen Albo, Rebeca Bailen, Pere Barba, Ana Benzaquen, Javier Briones, Ana Carolina Caballero, Antonio Campos, Ignacio Espanol, Christelle Ferra, Sebastian Garzon Lopez, Pedro Antonio Gonzalez Sierra, Luisa Maria Guerra, Rafael Hernani, Gloria Iacoboni, Ana Isabel Jiminez Ubieto, Mi Kwon, Lucia Lopez Corral, Oriana Lopez-Godino, Maria Carmen Martinez Munoz, Nuria Martinez-Cibrian, Juan Montoro Gomez, Laura Perez-Ortega, Guillermo Orti, Valentin Ortiz-Maldonado, Maria-Jesus Pascual, Maria Perera, Antonio Perez, Juan Luis Reguera, Jose M. Sanchez, Jaime Sanz, Anna Torrent, Lucrecia Yanez, Rosario Varela, Izaksun Ceberio Echechipia, Dolores Caballero, Anna Sureda
Summary: Anti-CD19 CART has been adopted as the standard third-line therapy for treating ABCL after failure of second-line therapy. This study compared the efficacy of CART with alloHCT and found that CART had similar progression-free survival to alloHCT, especially in patients with chemosensitive diseases. However, CART had lower non-relapse mortality.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Dipenkumar Modi, Samer Alkassis, Seongho Kim, Andrew Kin, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: We retrospectively evaluated allogeneic stem cell transplant (alloSCT) outcomes of 86 adult ALL patients in complete remission (CR) who received TBI-containing reduced intensity (RIC) and myeloablative conditioning (MAC). The study found no significant difference in survival rate between the RIC and MAC groups, but the MAC group had a lower relapse rate.
LEUKEMIA & LYMPHOMA
(2023)
Article
Cell & Tissue Engineering
Gu Zhenyang, Li Nainong, Wu Xiaoxiong, Wang Maihong, Fu Xiaorui, Wang Zhao, Ren Hanyun, Li Yuhang, Li Xiaofan, Wu Yamei, Liu Yao, Zhang Mingzhi, Wang Yini, Liu Daihong, Dong Yujun, Hu Liangding, Huang Wenrong
Summary: For patients with Peripheral T-cell lymphomas, an ATG-based Haplo-HSCT platform can serve as an alternative to MSD-HSCT. There were no significant differences in acute GVHD, chronic GVHD, relapse rates, non-relapse mortality, overall survival, and progression-free survival between the two transplantation approaches.
CELL TRANSPLANTATION
(2021)
Article
Hematology
Radwan Massoud, Hassan Naim, Evgeny Klyuchnikov, Dietlinde Janson, Christine Wolschke, Francis Ayuk, Nicolaus Kroeger
Summary: This study compared transplant outcomes between patients with refractory-T-NHL and Chemosensitive-T-NHL who underwent allo-SCT. While there were no differences in engraftment between the two groups, trends for improved survival were observed in the Chemosensitive-T-NHL group, showing the curative potential of allo-SCT in patients with T-NHL.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Biophysics
Dipenkumar Modi, Seongho Kim, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti
Summary: Our study found no significant difference in outcomes between myeloablative conditioning (MAC) and reduced intensity conditioning (RIC) regimens in haploidentical peripheral blood stem cell transplant (haploPBSCT).
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Paolo Corradini, Chiara Agrati, Giovanni Apolone, Alberto Mantovani, Diana Giannarelli, Vincenzo Marasco, Veronica Bordoni, Alessandra Sacchi, Giulia Matusali, Carlo Salvarani, Pier Luigi Zinzani, Renato Mantegazza, Fabrizio Tagliavini, Maria Teresa Lupo-Stanghellini, Fabio Ciceri, Silvia Damian, Antonio Uccelli, Daniela Fenoglio, Nicola Silvestris, Fausto Baldanti, Giulia Piaggio, Gennaro Ciliberto, Aldo Morrone, Franco Locatelli, Valentina Sinno, Maria Rescigno, Massimo Costantini
Summary: This study investigated the immune response to the SARS-CoV-2 vaccine in patients with tumors and immune disorders. The results showed that immunosuppressive treatment was a risk factor for a low humoral response, while the booster dose improved both humoral and T-cell responses.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Oncology
Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Paolo Elia Coppola, Pier Luigi Zinzani
Summary: Achieving minimal disease status before autologous stem cell transplantation (ASCT) is crucial for Hodgkin lymphoma (HL) patients. This retrospective study evaluated the effectiveness and safety of the BEGEV regimen as a first salvage treatment prior to ASCT in HL patients. The results showed that the BEGEV regimen was able to induce complete response in a significant number of patients with limited toxicity, and did not impair peripheral blood stem cell mobilization.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Alessandro Broccoli, Lisa Argnani, Paolo Elia Coppola, Marianna Gentilini, Gianmarco Bagnato, Ginevra Lolli, Matteo Carella, Laura Nanni, Alice Morigi, Beatrice Casadei, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani
Summary: After treatment with brentuximab vedotin, a proportion of patients who failed autologous stem cell transplantation for Hodgkin lymphoma can achieve and maintain long-term complete remission, indicating cure. The role of allogeneic transplantation in these patients is still being debated.
Review
Hematology
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles
Summary: Relapsed Mantle cell lymphoma (MCL) has a poor prognosis and there is no standard treatment. This study examined the outcomes of salvage therapy in MCL patients who failed Bruton tyrosine kinase inhibitor (BTKi) therapy, showing shorter overall survival in this group compared to those who received post-BTKi therapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Carmelo Carlo-Stella, Pier Luigi Zinzani, Anna Sureda, Luis Araujo, Olivier Casasnovas, Cecilia Carpio, Su-Peng Yeh, Krimo Bouabdallah, Guillaume Cartron, Won Seog Kim, Raul Cordoba, Youngil Koh, Alessandro Re, Daniela Alves, Martine Chamuleau, Steven Le Gouill, Armando Lopez-Guillermo, Ilidia Moreira, Marjolein W. M. van der Poel, Giovanni Abbadessa, Robin Meng, Ran Ji, Lucie Lepine, Rao Saleem, Vincent Ribrag
Summary: This study evaluated the safety, efficacy, and pharmacokinetics of a combination treatment of Cemi (anti-PD-1 receptor antibody) and Isa (anti-CD38 antibody) in patients with relapsed or refractory lymphoma. The results showed that the combination treatment had manageable safety and modest clinical efficacy in patients with cHL, DLBCL, and PTCL.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Sridhar Chaganti, Arie Barlev, Sophie Caillard, Sylvain Choquet, Kate Cwynarski, Anke Friedetzky, Eva Gonzalez-Barca, Natalia Sadetsky, Stefan Schneeberger, Dhanalakshmi Thirumalai, Pier L. Zinzani, Ralf U. Trappe
Summary: This study used a modified Delphi method to reach consensus among experts on the key characteristics of patients with EBV+ PTLD for whom chemotherapy may be inappropriate, providing guidance for clinicians in the treatment of this disease.
ADVANCES IN THERAPY
(2023)
Letter
Dermatology
Alessandro Pileri, Giacomo Clarizio, Corrado Zengarini, Beatrice Casadei, Elena Sabattini, Claudio Agostinelli, Pier Luigi Zinzani
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Oncology
John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H. Moskowitz, David Avigan, Joshua D. Brody, Vincent Ribrag, Alex F. Herrera, Franck Morschhauser, Abraham Kanate, Pier Luigi Zinzani, Jacob Bitran, Herve Ghesquieres, Stephen J. Schuster, Mohammed Farooqui, Patricia Marinello, Nancy L. Bartlett
Summary: The study evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL. The results showed that pembrolizumab had good efficacy in PMBCL in patients who were ineligible or failed hematopoietic cell transplantation, but its efficacy in other NHL subtypes was uncertain. Hematologic toxicities were common treatment-related adverse events.
LEUKEMIA & LYMPHOMA
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Lucia Zanoni, Davide Bezzi, Cristina Nanni, Andrea Paccagnella, Arianna Farina, Alessandro Broccoli, Beatrice Casadei, Pier Luigi Zinzani, Stefano Fanti
Summary: Non-Hodgkin lymphomas encompass a diverse group of lymphoproliferative disorders with varying clinical courses. 18F-FDG-PET/CT is the current gold standard diagnostic imaging for staging, restaging, and treatment evaluation in lymphomas with high glucose avidity. PET-based response criteria are now uniformly applied in FDG-avid lymphomas, and this article provides updates on the management of diffuse large B-cell lymphoma, follicular lymphoma, and other histotypes, as well as the use of PET-derived factors for patient stratification and prognostication, and emerging radiomics research. Published in Semin Nucl Med 53:320-351 (c) 2022 by Elsevier Inc.
SEMINARS IN NUCLEAR MEDICINE
(2023)
Article
Hematology
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Article
Pharmacology & Pharmacy
Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Summary: CAR T-cell therapy may cause cytokine release syndrome (CRS) and acute kidney injury, potentially affecting the pharmacokinetics of beta-lactam drugs. This study found that the clearance of meropenem and piperacillin did not need to be reduced in CAR T-cell patients experiencing CRS.
Article
Hematology
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz
Summary: The combination therapy of nivolumab and brentuximab vedotin showed long-term efficacy in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL), suggesting potential clinical applications.
Article
Hematology
Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, Pietro Quaglino, Branko Cuglievan, Emilio Berti, Naveen Pemmaraju, Francesco Onida, Rein Willemze, Alberto Orfao, Giovanni Barosi
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with recurrent skin nodules, aggressive clinical course, and poor prognosis. Due to its rarity, there is limited research, lack of controlled clinical trials, and absence of evidence-based guidelines for its management. This review presents recommendations and proposals by a panel of experts to address the unmet clinical needs in the management of BPDCN. The hope is that this comprehensive overview will improve the practice of BPDCN and guide future studies in the field.
Article
Hematology
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela Mckay, Sophie Leitch, Morton Coleman, Pier Luigi Zinzani, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Peter Browett, Xiaoyan Ke, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A. Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Summary: The final analysis of MAGNOLIA demonstrated that zanubrutinib provided sustained clinical responses and favorable safety/tolerability in patients with relapsed/refractory marginal zone lymphoma.
Article
Hematology
Stephen M. Ansell, Paul J. Brockelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trneny, Mariano Provencio, Ulrich Jaeger, Wolfgang Willenbacher, Rachael Wen, Alev Akyol, Joanna Mikita-Geoffroy, Margaret A. Shipp, Andreas Engert, Philippe Armand
Summary: This study demonstrates that nivolumab provides frequent and durable responses in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation failure. Results suggest that treatment can be discontinued after persistent complete remission and resumed upon disease progression.
Review
Oncology
Rui Wang, Aashiq Hussain, Quanquan Guo, Meimei Ma
Summary: DNA is highly immunogenic and can activate the cGAS-STING pathway, which plays a crucial role in the pathogenesis and progression of neoplastic diseases. The modulation of cGAS-STING signaling holds great promise for cancer therapy, although there are disagreements on whether to activate or inhibit this pathway.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Ali Zarezadeh Mehrabadi, Faezeh Shahba, Hossein Khorramdelazad, Nazanin Aghamohammadi, Milad Karimi, Kowsar Bagherzadeh, Majid Khoshmirsafa, Ramin Massoumi, Reza Falak
Summary: IL-1 receptor accessory protein (IL-1RAP) plays a crucial role in inflammatory conditions and tumorigenesis in the tumor microenvironment. It is involved in the progression, metastasis, and angiogenesis of solid tumors and hematological malignancies.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Xiao Tang, Yujie Niu, Jinli Jian, Yuancheng Guo, Yin Wang, Yu Zhu, Bei Liu
Summary: Ferroptosis is an iron-dependent form of cell death that promotes tumor cell death by causing cell membrane rupture and accumulation of lipid peroxides. Extensive research has been conducted to explore the mechanism of ferroptosis inducers, but its role in hematological tumors is still limited.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Tanwei Yuan, Dominic Edelmann, Jakob N. Kather, Ziwen Fan, Katrin E. Tagscherer, Wilfried Roth, Melanie Bewerunge-Hudler, Alexander Brobeil, Matthias Kloor, Hendrik Blaeker, Barbara Burwinkel, Hermann Brenner, Michael Hoffmeister
Summary: The study aimed to analyze and validate previously published CpG-methylation-based prognostic biomarkers and prediction models for colorectal cancer (CRC) prognosis. The results showed that the discrimination ability of the models was insufficient and lacked clinical relevance.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Zhihui Duan, Dandan Yang, Ping Yuan, Xiaoming Dai, Guodong Chen, Daichao Wu
Summary: This article provides a comprehensive overview of therapeutic cancer vaccines, including their classification, clinical application, efficacy, and combination strategies with other therapies. It offers a valuable theoretical basis for the future clinical application and development of therapeutic cancer vaccines.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)